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Introduction 
It is perhaps pretentious to employ the current 
popular term ‘antiviral chemotherapy’ when only 
three classes of compounds are officially approved for 
limited clinical application: N-methylisatin3&io- 
semicarbazone as a prophylactic agent in smallpox 
[ 1 ] ; adamantamine, for prophylaxis in humans sub- 
ject to influenza A-2 virus infections [2,3] ; and 5- 
iodo-2’-deoxyuridine (IUdR) for therapy of herpes 
simplex cornea1 keratitis [4-71, a major source of 
blindness in man. 
Differences of opinion still exist as to whether the 
future lies with antiviral agents of vaccines [2], the 
latter of which exploit natural defence mechanisms 
[8,9] . However specific immunization is feasible only 
in prophylaxis of viral infections which possess a 
limited number of serotypes. The feasability of de- 
signing broad-spectrum antiviral agents (see below) 
will provide the decisive answer to this question. 
The vast majority of new antiviral agents reported 
during the past 10 years do not pass the stage of tests 
on cell cultures or small animals. But the intense 
research activity of the past 5 years has provided a 
number of drugs approved for investigational pur- 
poses, many of which are promising. This brief out- 
line concentrates on only a limited range of com- 
pounds, mainly nucleoside and poly(nucleotide) 
analogues, principally with a view to illustrating 
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methods of approach, applicable also to other com- 
pounds. An extensive compilation of antiviral (and 
antitumour) substances of natural origin has appeared 
[lOI. 
Antiviral and antitumour agents 
The search for new or improved antiviral agents has 
now become inextricably linked with similar endeav- 
ours in the field of antitumour agents, stimulated enor- 
mously by the discovery of reverse transcriptase 
which clarified the molecular mechanism of tumour 
induction by oncornaviruses [ 1 l] , in at least appar- 
ent agreement with the known fact that some oom- 
pounds are therapeutically effective both as antiviral 
and antitumour agents. 
Of the three types of DNA viruses known to in- 
duce tumours, viz. the adenoviruses, papova viruses 
and herpes viruses, the latter are very widespread and 
persistent in humans, who display increased suscepti- 
bility on immunosuppression treatment. Herpes viruses 
cause cancer in animals and there is extensive evidence 
for and intimate association between these viruses and 
malignancies in man; the interest in this subject is tes- 
tified to by the number of symposia [ 12- 141 and re- 
views [ 15-171 during the past 2 years. It is of special 
interest that no vaccines have been developed against 
herpes. 
Some viruses are also known to be responsible for 
severe deformities both in animals and man; but the 
role of viruses in congenital malformations, although 
considered established, is less well known. The sub- 
ject of viral teratogens has been recently reviewed 
[181. 
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Mode of action of antiviral agents 
The most promising aspect of present-day research 
is the increasing attention being devoted to the mode 
of action of potential antiviral agents. Most of these 
act at steps subsequent o uncoating, and will be 
discussed below. One exception is adamantamine and 
some of its derivatives, the activity of which is direc- 
ted against some early step in penetration or against 
uncoating following penetration [ 191. Another speci- 
fic inhibitor of the uncoating process in the case of 
ECHO virus [20] is 2-thio+oxothiazolidine, which 
reacts reversibly with the coat protein. Eggers (Sept. 
1973 Congress on Viral Chemotherapy) reports that 
this compound at 100 ng/ml gives a 4-log decrease in 
viral replication, while 150 pg/ml is not toxic to the 
cell, nor affects cellular RNA or protein synthesis. 
The review by Dales [21] on early events in cell- 
animal virus interactions is very timely with respect 
to the activity of such agents. Meanwhile Welsh et al. 
[22] have found that adamantadine*HCl effectively 
inhibits lymphocytic choriomeningitis virus synthesis 
even when added after all the cells were infected; 
virion penetration was also delayed, so that the agent 
is apparently effective both in the early and late 
stages of infection. 
Estimation of viral susceptibility 
General experimental procedures for determination 
of antiviral activities in vitro and in vivo, together 
with associated toxicities and the resulting therapeu- 
tic indices, are described in the volume edited by 
Bauer [ 1 ] . A more recent and interesting innovation 
is the development of laboratories for the rapid clini- 
cal diagnosis of common viruses, as well as their sus- 
ceptibilities in tissue culture to various antivital 
agents available to the clinician (e.g. [23,24]). 
Purine and pyrimidine derivatives 
The literature literally teems with reports of purine 
and pyrimidine analogues exhibiting antiviral activity 
[25-271, but many should be treated with reserve 
because of a paucity of adequate data. A notable 
exception is 5fluorouracil, probably the most inten- 
sively investigated pyrimidine antimetabolite; it is 
readily converted to the riboside in both bacterial and 
mammalian systems, followed by phosphorylation 
and incorporation into RNA in the case of mammal- 
ian cells. But, while active against DNA viruses in cell 
cultures, its in vivo efficacy is limited [28,29] . 
In a recent exemplary study [30] on the synthesis 
of Rous sarcoma virus on monolayer cultures of chick 
embryo fibroblasts, it was shown that S-fluorouridine 
inhibits cellular RNA synthesis by more than 80%, 
largely by irreversible blockage of formation of 
rRNA. Although normal quantities of virus are pro- 
duced, the infectivity was lowered; correlating with a 
profound inhibition of viral glycoprotein synthesis. 
Under the same conditions 5fluorouracil did not 
affect the yield of infectious virus. By contrast, 
another nucleoside analogue, 5-bromotubercidin, 
reversibly blocked synthesis of heterogeneous nu- 
clear, as well as ribosomal, RNA; it also blocked syn- 
thesis of RSV-RNA and, after a lag period, synthesis 
of viral proteins and mature virions. 
Both 6-thioguanine and its riboside exhibit high in 
vitro activity against cytomegalovirus, a highly infec- 
tive virus found in patients on immunosuppressive 
treatment, and responsible for severe congenital ef- 
fects in newborn infants. The therapeutic index for 
both of these is exceptionally high, about 100, and 
several additional analogues were almost as active 
[31]. It is of interest that 6thioguanine is very effec- 
tive in combination antitumour therapy with araC 
[32-341. 
A remarkable example of a pyrimidine analogue 
with antiviral activity is 5-(3,4-dichlorophenyl)-5- 
ethyl-hexahydropyrimidine-2,4,6-trione [35] . This is 
more easily recognized as a barbital derivative, 5- 
ethyl-5’-(3,4-dichlorphenyl)barbital. It was the only 
member of a large number of clinically useful barbitu- 
rates, with weak activity against Coxsackie A2 1 virus 
on AV2 cells by the plaque reduction test. But, when 
administered in the diet to mice and gerbil at lo-70 
mg/kg daily, it gave a high protective effect with a 
therapeutic index in excess of 12. Since this com- 
pound is a member of a class regarded as clinically 
safe, and is effective orally, trials in man appear to be 
indicated. Worthy of note is the fact that, on the 
basis of in vitro tests alone, this analogue would have 
been rejected. 
One further example is 5-methyl-6-carbethoxy-2- 
thiomethyl-pyrimidine, which has been reported high- 
ly active in vitro against polio [36] . 
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Nucleoside analogues 
Nucleoside analogues, both synthetic and of natur- 
al origin, have provided some of the most potent 
antiviral, and antitumour agents. Interest in this class 
of compounds stems in large part from the progress 
achieved in recent years on the metabolism, and the 
replication mechanisms, of nucleic acids, facilitating 
studies on the mechanism of action of these analo- 
gues, as well as the ‘rational’ design of new ones. A 
nucleoside analogue, 5-iodo-2’-deoxyuridine (IUdR) 
was the first purely synthetic antiviral agent, with 
effective in vitro activity against herpes simplex, 
vaccinia and some other virulent viruses, and with 
beneficial effects in clinical treatment of cornea1 
herpes and, to a lesser extent, cutaneous herpes, 
herpes zoster, herpes genitalis and herpes encephalitis 
[4-71. 
A number of additional nucleoside analogues sub- 
sequently proved effective against herpes, including 
araC, 5fluorodeoxyuridine (FUdR), 5-bromodeoxy- 
uridine (BUdR), 5-methylamino-2’-deoxyuridine, 
araA, 5-trifluoromethyl-2’-deoxyuridine, 5-ethyl-2’- 
deoxyuridine. The relative clinical merits of some of 
these are reviewed by Kaufman [6], e.g. trifluoro- 
thymidine is superior to IUdR for treatment of 
dendritic keratitis. The mode of action of these vari- 
ous analogues clearly cannot be identical; this is re- 
flected in their range of action, e.g. 5-methylamino- 
deoxyuridine is inactive against other viral systems; 
IUdR is more effective that FUdR against herpes type 
1, whereas the reverse is true for type 2. By contrast, 
araC inhibited both types equally, whereas all three 
were inactive against adenoviruses. In turn, araA is 
active against IUdR-resistant herpes. 
The mode of action of IUdR and BUdR is still the 
object of intensive study [5,7] . Although results vary 
somewhat with the test system employed, they appar- 
ently undergo conversion to the triphosphates, follow- 
ed by incorporation into viral DNA, with possibly re- 
sultant inhibition of mRNA transcription [37]. 
The biochemical effects of araA have been tho- 
roughly reviewed by Suhadolnik [38]. Like most 
nucleoside analogue antiviral agents, it is converted 
intracellularly to the triphosphate, which inhibits 
ribonucleotide reductase (but less efficiently than 
dATP) and DNA polymerase [39]. It is apparently 
not incorporated into DNA or RNA [40]. Prior to 
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phosphorylation it is slowly deaminated in vivo; the 
resultant ara1 is equally effective, an advantage not 
shared by other analogues, such as araC (see below). 
AraC biochemistry is exhaustively reviewed by 
Cohen [41], Roy-Burman [29] and Goz and Prusoff 
[4]. Earlier proposals implicating araCDP as an inhi- 
bitor of CDP reductase no longer appear valid. By 
contrast araCTP selectiudy inhibits some polymerases 
(see below) and is incorporated into DNA; but a dif- 
ference of opinion still exists as to whether it acts 
solely as a chain terminator [42] or is also incorpo- 
rated within the DNA strands [43] . Particularly note- 
worthy is the fact that araC is active against oncoge- 
nit viruses, and is widely employed singly, or in com- 
bination tumour therapy [32-341. 
The mode of action of trifluorothymidine involves 
phosphorylation to the triphosphate, which then re- 
places 2-8% of the thymidine in the DNA of vaccinia 
virus. This, together with the observed morphological 
changes in the virus particles, is believed to account 
for the antiviral effect. However the 5’-monophos- 
phate is a powerful inhibitor of thymidylate synthe- 
tase, a fact perhaps not without significance [44]. 
5-Alkyl nucleosides 
The antiviral activity of some nucleoside analogues 
is due, at least in part, to their incorporation into 
DNA (see above). For such analogues as IUdR and 
BUdR, this may entail accompanying mutagenic 
effects, as well as activation of oncogenic genomes. 
Hence the potential utility of an analogue which 
might exhibit base-pairing properties identical with 
the parent base, thus minimizing or eliminating possi- 
ble mutagenic effects. 
5-Ethyluracil is such an analogue of thymine; the 
pK for dissociation of the ring Na hydrogen (the 
donor in Watson-Crick base pairing) in 5-ethyluracil 
and its pentosides is identical with those for thymine 
and thymidine. Furthermore 5-ethyluracil undergoes 
moderate incorporation into bacterial DNA and 5- 
ethyldeoxyuridine (EtUdR) extensive incorporation 
into phage DNA. In reversions of T4 rI1 mutants to 
r+, where BUdR gives the expected frequencies of re- 
vertants, EtUdR was without effect [27]. EtUdR 
restores cell proliferation in human phytohemag- 
glutinin-stimulated lymphocytes grown under condi- 
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tions of DNA synthesis block due to amethopterine 
induced thymidine deficiency, with incorporation 
into nuclei of cells entering the S phase; the analogue 
induced no chromatid aberrations in metaphase under 
conditions where BUdR did so [45]. 
EtUdR was found to be almost as effective as 
IUdR and BUdR against vaccinia virus on HeLa cells 
[46] , and was somewhat less effective than IUdR 
against herpes simplex on chick embryo fibroblast 
monolayers (H. Kaufman, personal communication). 
Other reports of activities against these viruses are 
even more promising ([47] and references therein), 
and further trials are now under way with Dr. E. 
DeClercq. Meanwhile S-ethyl-2’-deoxycytidine has 
been synthesized [48]; in tests conducted by DeClercq 
against herpes,.vaccinia nd VSV viruses on primary 
rabbit kidney cells, it exhibited weak activity only 
against herpes, probably via cellular deamination to the 
active EtUdR [48]. 
The mode of action of EtUdR is under study. The 
low incorporation of S-ethyluracil into E. coli DNA 
(about 15% replacement of thymine) is due in part to 
its poor properties as a substrate of thymidine phos- 
phorylase. EtUdR is a moderate inhibitor of thymi- 
dine kinase and is itself a poorer substrate than thy- 
midine [47]. 
Muraoka and Ueda [49] have synthesized 5-ethyl- 
uracil-1 -fl-D-galactopyranoside and the corresponding 
xylopyranoside, both of which were claimed to ex- 
hibit appreciable activity against the Mahoney strain 
of polio virus. However the earlier claims of these 
authors for antiviral activities of several other S-alkyl- 
uracil ribonucleosides, in particular, 5butyluridine, 
have not been confirmed [50] ; undoubtedly the 2’- 
deoxyuridine would be of more interest. 
Nucleoside anomers and enantiomers 
Chemical syntheses of 2’-deoxynucleosides yield 
mixtures of the Q- and fl-anomers, the separation of 
which is usually tedious (but see ref. [51]). It is fre- 
quent practise to discard the ‘biologically inactive’ 
cu-anomer. Two recent reports point to the need for a 
revision of this concept. 
Christensen et al. [52] found the cy-anomers of 2- 
chloro- and 2-hydrazino-2’-deoxyadenosine to exhibit 
appreciable activity against several bacterial systems 
and, albeit to a lesser extent than the /3-anomer, 
against leukemia L1210. Activity was not due to 
cleavage of the glycosidic bond. 
The foregoing recalls the earlier report by Peery 
and LePage [53] that both the (Y- and /3-anomers of 
2’-deoxy-6-thioguanine inhibit some mouse tumours. 
The a-anomer was less active, but also less toxic to 
the host because it was converted to the active nu- 
cleotide by tumours (including human) but not by 
normal bone marrow cells. The lower toxicity made 
possible higher and multiple doses with concomitant 
enhanced activity. 
No tests of antiviral or antitumour activities appear 
to have been made with the cr-anomers of ribo- and 
arabinonucleosides. But it should be noted that traces 
of cvcytidylic acid have been isolated from yeast RNA 
[54]; while two cytosine nucleosides possessing the (Y- 
L configuration, pentopyranine A and C, are elabo- 
rated in the culture medium by the Blasticidin S-pro- 
ducing microorganism Streptomyces griseochromoge- 
nous [55]. 
The L-enantiomer of araC, although resistant to 
enzymatic deamination, proved inactive against lym- 
phoid leukemia L1210 and Ridgeway osteogenic sar- 
coma [56]. 
Nucleotide analogues 
Nucleoside antiviral and antitumour agents are 
usually converted intracellularly to the active phos- 
phorylated forms. But some cells may not contain the 
necessary nucleoside kinase(s); others, rich in nucleo- 
side phosphorylase, may cleave the glycosidic linkage 
before phosphorylation occurs. 
Nucleotides are usually incapable of penetrating 
the cellular membrane because of the diionized phos- 
phate group at physiological pH. Wigler and Lozzio 
[57] overcame this difficulty by preparing the me- 
thyl ester of BUdR-5’-phosphate, which readily pene- 
trated Chinese hamster cells intact and killed all the 
cells over a time interval equivalent to 8 generation 
cycles. It was postulated that BUdR-5’-methylphos- 
phate is transformed by thymidylate and dTDP 
kinases to the triphosphate, followed by incorpora- 
tion into DNA with resultant lethality. But another 
possibility not envisaged is the intracellular hydrolysis 
of this analogue by phosphodiesterase I to BUdR-5’- 
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phosphate [58] , followed by phosphorylation to the 
normal triphosphate. 
An interesting variant of the foregoing [59] pro- 
fited from the observation [60] that CAMP is resis- 
tant to muscle AMP deaminase and crosses cell mem- 
branes intact. This suggested 3’,5’-cyclic-araCMP, 
which proved as active in vitro as araC against several 
DNA viruses. In infected mice it proved more active 
than araC against herpes and vaccinia, presumably 
because of resistance to deamination by deoxycyti- 
dylate deaminase. It was not established whether the 
enhanced antiviral activity was a property of the cyc- 
lic phosphate derivative, or was preceded by cleavage 
of the cyclic phosphate ring by cyclic phosphodiester- 
ase. The same authors had earlier shown that some 
3’,5’-cyclic phosphates of adenosine analogues resis- 
tant to CAMP phosphodiesterase, xhibit antiviral ac- 
tivity. It should be noted that the replacement of 
araC by its 3’,5’-cyclic phosphate also obviates the 
deleterious effects on araC activity of intracellular 
cytidine deaminase (see below). 
Both the foregoing procedures are clearly promis- 
ing and applicable on a wider scale. It should be re- 
called that 2’-acylated CAMP is without effect on gly- 
cogen phosphorylation in vitro, but is more active 
than CAMP when tested on liver slices, the obvious 
interpretation being that the acylated derivative more 
readily crosses the cell membrane and is then hydro- 
lyzed by cellular esterase(s) to the active CAMP [61]. 
cinogens (shown to be also mutagens, see ref. [62]), 
X-rays, specific antigens, etc., in accord with both the 
‘provirus’ and ‘oncogene’ hypotheses. It has now been 
established that IUdR and BUdR are potent activa- 
tors of MLV in AKR cells, the extent of activation 
being as high as 106-fold the spontaneous rate [63]. 
Klement (see ref. [63]) also found BUdR to activate 
synthesis of murine sarcoma virus in a nonproducer 
line of rat cells transformed by Kirsten sarcoma virus. 
According to the authors, “these drugs may be ex- 
tremely useful agents for activating a leukemia virus 
genome in cells from mice and other species, includ- 
ing man”, but this is no comfort to those interested in 
development of antiviral agents. Meanwhile Vesely 
and Cihak [64] found that 5-azacytidine is also an acti- 
vator, and Gerber [65] that BUdR activates 
Epstein-Barr virus in human lymphoid cells. Fortun- 
ately several other nucleoside antiviral agents, such as 
araC, 6-azauridine, 6-mercaptopurine are reported to 
be inactive. In a comparative study of IUdR and 
EtUdR, I.B. Weinstein (personal communication) 
found the latter inactive. 
Intracellular potentiation of activity 
Hazards associated with nucleoside antiviral agents 
Apart from potential toxicity to the host associa- 
ted with the in vivo use of any drug, the properties of 
several antiviral nucleosides call for special comment, 
e.g. IUdR has been employed on a number of patients 
with herpes simplex encephalitis, and FUdR and 
IUdR against congenital cytomegalovirus infections 
[5] . Both these analogues are incorporated into DNA 
and are mutagenic. The ability of another analogue, 
BUdR, to produce chromosomal aberrations (see 
above) is well known. Clinical use of such agents for 
other than topical applications are consequently 
limited to cases of potentially lethal infections. 
The intracellular metabolism of drugs is by no 
means a new problem (e.g. [66]) and antiviral and 
antitumour agents are no exception. Occasionally 
intracellular enzymes play a key role in formation of 
the active agent, e.g. phosphorylation of nucleoside 
analogues, discussed above. Following are several illu- 
strations of procedures developed to circumvent the 
deleterious effects of intracellular enzymes on anti- 
viral and antitumour agents. 
The use of araC as a therapeutic agent requires 
complex dose schedules, largely due to its rapid intra- 
cellualr deamination to inactive araU. In patients 
treated for acute myeloblastic leukemia the half-life 
of araC in the plasma varied from 3-9 min [67], and 
its efficacy has been linked directly with the level of 
cytidine deaminase in the bone marrow of leukemic 
patients [68]. The distribution of deaminases (and 
kinases) of araC in tissues of the mouse and man 
have been investigated by Ho [69]. 
An additional hazard now attaches to the fore- The activity of araC in L1210 leukemic mice is 
going. It has long been known that murine leukemia enhanced upon simultaneous administration of 
virus (MLV) may be ‘activated’ in mice by aging, car- 3,4,5,6_tetrahydrouridine, a known potent inhibitor 
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of cytidine deaminase [70]. Additional deaminase 
inhibitors have been developed, such as N4-hydroxy- 
S-methyl-2’-deoxycytidine [71]. It has been pro- 
posed [72] that such inhibitors be employed with 
5azacytidine, a promising agent in treatment of acute 
myelocytic leukemia, the activity of which is reduced 
as a result of its deamination by peripheral leukemic 
leucocytes. But more efficient methods have now 
been developed to circumvent the deleterious effects 
of tissue deaminases. 
It was initially found by Hoshi et al. [73] that 
2,2’-anhydro-araC is markedly active at high dose 
levels against mouse leukemia L1210, with a thera- 
peutic index of 50 as compared to 10 for araC; the 
increased activity was ascribed to the resistance of 
araC to tissue deaminases. Simultaneously Nagyvary 
(cited in ref. [38]) reported that 2,2’-anhydro- 
araC3’phosphate was active against Rauscher leuke- 
mia virus and leukemia due to this virus in mice, and 
suggested that this was due to hydrolysis of the com- 
pound to active araC in the blood stream, results 
confirmed and extended by numerous observers (e.g. 
ref. [74] ). Anhydro-araC is also inherently unstable 
and is converted slowly to araC in neutral medium, 
with a half-life at pH 7.4 and 37°C of 32 hr; it does 
not undergo phosphorylation in vivo, nor is it taken 
up by Ehrlich ascites cells prior to conversion to araC; 
furthermore an araC resistant 2’-deoxycytidine 
kinase-deficient subline of L12 10 in mice was cross- 
resistant to 2,2’-anhydro-araC [75]. The cumulative 
toxicity of the cyclocytidine derivative is surprisingly 
low relative to araC [76]. It is clear that 2,2’-an- 
hydro-araC is a depot form of araC, the effectivity of 
which is now under intensive investigation (see also 
below). 
Another approach to the development of sustained 
action derivatives of araC arose out of the synthesis 
of the 5’-ester of araC with adamantane-1-carboxylic 
acid. The resulting araC-5’-adamantoate proved to be 
a much more effective antitumour agent than araC, 
with single-dose therapy as efficient as therapy with 
araC on an optimum schedule of courses of multiple 
closely spaced doses with appropriate intervals for 
host recovery [77]. Further investigation demon- 
strated that the drug is hydrolyzed by mammalian 
blood plasma (probably by non-specific esterases) to 
active araC [78] . This principle had been applied 
much earlier by Nishizawa et al. [79] who used esters 
of 5fluoro-2’-deoxyuridine to reduce hydrolysis by 
cellular nucleoside phosphorylase. Subsequently a 
variety of other 5’-esters of araC were shown to be 
equally effective as antitumour agents in mice, in 
protecting mice from the lethal effects of intracranial 
herpes simplex infection, in inhibition of DNA syn- 
thesis in phytohemagglutinin-stimulated human lym- 
phocytes, etc. [80] . The corresponding 2’-O- and 
3’-O-esters proved less effective [81,82] . 
There is little doubt but that the foregoing esters 
are protected from in vivo deamination prior to 
hydrolysis of the ester substituents. This is supported 
by the direct synthesis of all the possible Or-methyl 
and O’-ethyl derivatives of araC, which proved highly 
or totally resistant to kidney cytidine deaminase 
[83-851, and which exhibit low, if any, activity 
against several viruses in cell culture (DeClercq and 
Shugar, in preparation), in accordance with the ex- 
pected resistance of such derivatives to esterases and 
other tissue enzymes. It is of interest that 2’-O- 
methyl-araC, which is theoretically capable of being 
converted to the 5’-triphosphate, is inactive, pointing 
to the importance of the unsubstituted arabinosyl 
ring for its activity. 
An ingenious application of two of the foregoing 
principles involved the synthesis of 2,2’-anhydro-ara- 
5-fluorocytosine [86] . This was expected to undergo 
hydrolysis to ara-5fluorocytosine (ara-FC), followed 
by deamination to ara-5fluorouracil (ara-FL-J), as in 
scheme 1. Each of these is chemotherapeutically 
active by inhibition of DNA polymerase and thymi- 
dylate synthetase, respectively. Experiments demon- 
strated, in fact, significant prolongation of survival 
times in mice innoculated with leukemia L12 10 and 
its mercaptopurine-resistant variant L12 1 O/6-MP, 
when administered as a single daily dose, or.even 
orally and as much as 48 hr after infection, so that 
this ‘double-barreled’ agent proved more effective 
than araC, ara-FC, anhydro-araC or ara-FU. 
An additional illustration of the use of intracellular 
enzymes for enhancing drug efficiency was provided 
by LePage et al. [87] . When a nucleotide, such as the 
antiviral araAMP, was administered to mice, it was 
rapidly excreted at the same rate and in the same 
form as if the nucleoside were administered, due to 
the high kidney phosphatase level. But human kidney 
samples were found to have much lower phosphatase 
levels, and administration of the nucleotide to human 
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patients led to a slow conversion to nucleoside, result- 
ing in a sustained blood plasma level of the latter. 
This procedure possesses the additional advantage 
that nucleotides are more soluble and may be given 
intravenously in small volume. It should be noted 
that araA is readily deaminated to araI by intracel- 
lular adenosine deaminase, but in this instance the 
antiviral activity of the latter against herpes simplex is 
equal to that of araA [6]. 
Broad-spectrum antiviral agents 
Practically all antiviral agents hitherto reported 
possess a limited spectrum of activity, with the excep- 
tion of interferons (which exhibit species specificity) 
and interferon inducers, whose value is mainly pro- 
phylactic. 
The possibility of developing broad-spectrum anti- 
viral agents was demonstrated by Bauer et al. [88] . It 
had been commonly accepted that methisazone 
(N-methyl-isatin3-thiosemicarbazone), an effective 
agent against smallpox, is active only against some 
DNA viruses. The foregoing authors found that this 
agent, and some of its analogues, are active against a 
variety of RNA viruses in tissue culture, including 
foot-and-mouth, polio, some rhinoviruses, arboviruses 
and influenza A and B. No in vivo results were 
reported. The activity against RNA viruses was con- 
sidered in accord with the mode of action of this 
agent which, in the case of vaccinia, induces dissolu- 
tion of the late mRNA-ribosome complex, with 
concomitant loss of ability to synthesize proteins 
required for encapsidation of newly formed viral 
DNA [89]. 
Swallow [3] and, indirectly Dales [21] , have 
drawn attention to the broad antiviral spectra of the 
adamantamines. For example a-methyl-1 -adamantane 
methylamine hydrochloride not only provides signif- 
icant protection against influenza A-2 in mice even 4 
days after infection, but shows in vitro activity 
against rubella, rubeola and Rous and Esh sarcoma 
viruses; while adamantamine itself is active in vitro 
against lymphocytic choriomeningitis [22] . 
The ribofuranosyl nucleoside antibiotic, pyra- 
zomycin, isolated in 1969 by R.H. Williams, of the 
Lilly Research Laboratories from a strain of Strepto- 
coccus candidus, was found to prevent proliferation 
of rhinovirus, measles, herpes simplex and vaccinia in 
cultured cell monolayers, with a minimum inhibitory 
concentration for vaccinia of less than 2 pg/ml. Vac- 
cinia virus lesions in mice were reduced even on oral 
administration. 
Pyrazomycin is structurally related to the nucleo- 
side antibiotics formycins A and B (analogues of 
adenosine and inosine, Scheme 2), both with antiviral 
activity [90]. The biologically active form of pyrazo- 
mycin has been identified as its 5’-phosphate [91] , 
which is an antagonist of uridine metabolism, being 
20-fold more potent than 6-aza-UMP as an inhibitor 
of orotidylic acid decarboxylase. Antitumour activity 
of pyrazomycin has been investigated by Sweeney et 
al. [92]. 
The relatively broad antiviral spectrum of pyrazo- 
mycin prompted the synthesis of a number of ribo- 
furanosides of 5membered heterocyclic rings, culmi. 
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OH OH 
Pyraromycin 
04-i OH OH OH OH OH 
Formycin A Formycin B 
SCHEME 2 
Virazole 
nating in 1 Q-D-ribofuranosyl-I ,2,4-triazole-3-carbox- 
amide, denoted as Virazole [93,94], and exhibiting 
highly significant in vitro activity against 7 DNA and 
10 RNA viruses tested. In vivo experiments were 
equally promising: topical application inhibited 
herpes keratitis in rabbits, and tail lesions induced by 
herpes, vaccinia and vesicular stomatitis viruses in 
mice. Intraperitoneally in mice it inhibited Friend 
leukemia virus-induced splenomegaly and hepato- 
megaly, as well as respiratory infections by influenza 
A,,, AZ, Band parainfluenza 1 viruses. Intracerebral viral 
infections were unresponsive, perhaps because the 
drug does not effectively penetrate the blood-brain 
barrier [95-971. The oral activity in IV/A2 -infected 
mice was independently confirmed in three other 
laboratories [96] and is especially significant since 
only adamantanamine l HCl had hitherto proven effec- 
tive against influenza A and AZ virus infections, and 
only prophylactically; Virazole exhibited significant 
therapeutic value even when administered 24 hr after 
infection. 
It is clear that, apart from its potential therapeutic 
significance, the availability of an agent with such a 
broad antiviral spectrum should prove a useful tool in 
studies on the biochemical mechanisms of viral repli- 
cation and inhibition. Virazole is not an interferon 
inducer in cell cultures or mice [95]. Its action 
against measles virus in Vero cell cultures is reversed 
by xanthosine, guanosine, less so by inosine. In vitro 
studies with isolated enzyme systems showed that the 
5’-phosphate is a potent competitive inhibitor of 
5’JMP dehydrogenase, with resultant blocking of 
5’-GMP synthesis in infected cells on the pathway 
from 5’-IMP to 5’-XMP 1981. Although demonstrated 
that virazole undergoes phosphorylation in vivo, 
further studies are necessary to clarify its mode of 
action. Meanwhile some additional analogues have 
been prepared, but none was more active than the 
parent compound, nor did any exhibit broad- 
spectrum activity [99]. 
It is to be anticipated that this important develop- 
ment will stimulate further efforts in this direction, in 
the same way as the first synthetic antiviral agent, 
IUdR, initiated the era leading to the present state of 
progress. 
Inhibitors of viral polymerases 
The discovery of RNA-directed DNA polymerases 
in oncornaviruses provided a new impetus in the 
search for selective inhibitors of polymerases not only 
for tumour therapy, but against other viral infections 
as well.. 
Earlier observations had already pointed to the 
possibility of selective inhibition of polymerase 
activity. Cleaver [loo] found that hydroxyurea effec- 
tively blocks semi-conservative DNA replication in 
HeLa cells without affecting repair replication. It was 
subsequently noted by Brown [loll that 6-@-hy- 
droxyphenylazo)-uracil completely inhibited semi- 
conservative DNA replication in Gram-positive orga- 
nisms, while allowing normal repair replication of 
W-damaged DNA to proceed in B. subtilis 168 thy- 
ind; in agreement with this was the observation that 
this agent did not inhibit DNA pol I in vitro. Simul- 
taneously Gamma Reddy et al. [102] showed that, in 
in vitro systems, araCTP inhibits E. coli DNA pol 
III, to a much lesser extent pol II and T4 bNA poly- 
merase, and is without effect on DNA pol I, pointing 
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to the utility of araCTP for studies of repair replica- 
tion in the absence of semi-conservative replication. 
But no less significant is the fact that such selective 
inhibition is exhibited by the active form of an agent 
with potent antiviral and antitumour properties. It 
was, in fact, shortly afterwards demonstrated [ 1031 
that araCTP is a potent inhibitor in vitro of partially 
purified Rauscher leukemia virus (RLV)-DNA poly- 
merase, using either RNA or DNA templates, in 
accord with the known activity of araC against oncor- 
naviruses, and the generally accepted belief that its 
activity depends on its intracellular transformation to 
the triphosphate, which then interferes with DNA 
replication. 
Screening of 1000 synthetic compounds for selec- 
tive inhibition of Q/3 replicase yielded one, 4-(2-propi- 
nyloxy-/3-nitrostyrene), which at 10 pg/ml inhibited 
phage multiplication in E. coli by 99% with only 50% 
inhibition of bacterial growth and no inhibition of 
DNA polymerase. The replicases from poliovirus- 
infected cells, and Friend leukemia virus-infected 
tissues, were strongly inhibited by this agent at 100 
I.cg/ml, but no in vivo trials were reported [ 1041. 
Various classes of molecules have been found 
which block reverse transcriptases in vitro, including 
the ansamacrolides (rifamycins, streptovaricins), 
anthracyclines (daunorubicin, adriamycin, etc.), cacti- 
nomycins, polypeptides (distamycins, bleomycins), 
etc. All of these, and what is known of their mode of 
action, have been admirably reviewed by Chandra et 
al. [105] and Apple [106]. 
The most popular of the foregoing is the antibiotic 
rifamycin-SV and some of its semi-synthetic analo- 
gues, which specifically bind to, and block, DNA- 
directed bacterial RNA polymerases, but do not 
inhibit mammalian polymerases. The potential clini- 
cal applications and antiviral activities of the rifamy- 
tins are reviewed by Wehrli and Staehlin [ 1071, who 
refer to this class of compounds as the ‘wonder drug’, 
but more useful as a biochemical ‘tool’ because of the 
high toxicity of therapeutic doses. Of 180 rifamycin 
derivatives screened by Green et al. [ 1081 and Gurgo 
et al. [ 1091 for activity against RNA- and DNA- 
directed activities of various RNA tumour viruses, a 
number showed promise, but no toxicity data were 
presented. 
Another potential complication in the search for 
specific inhibitors of RNA-directed DNA polymerase 
S56 
is the demonstration of such enzymes in HeLa cells 
derived from a cervical carcinoma, and in WI-38 cells, 
a normal diploid strain from human embryonic lung 
tissue [ 1 lo] . The existence of such enzymes of appa- 
rently cellular origin may complicate the design of 
specific inhibitors for reverse transcriptases. Further- 
more, can one expect reverse transcriptase inhibitors 
to be therapeutically effective if the function of this 
enzyme is necessary only to initiate the transformed 
state, but not to maintain it? It is true that thera- 
peutic effects have been demonstrated both in ani- 
mals and man [ 1061, but the data presently available 
are too meagre to provide an unequivocal answer. 
Clearly more extensive studies on the role of reverse 
transcriptase inhibitors as function of template requi- 
rements are called for. 
Polynucleotide inhibitors of viral poiymerases 
An additional, and newer, approach to selective 
inhibition of viral replicases makes use of synthetic 
polynucleotides which to some extent mimic part of 
the viral genome. For example, following the dis- 
covery that the initial portion of RNA transcribed 
from Q/3 RNA is rich in adenosine, it was shown that in 
vitro replication was appreciably inhibited by poly 
(rU) or the copolymer poly (rA,rU), and less so by 
poly (rA) [ 1111. 
With increasing knowledge of viral genomes and of 
the template requirements of viral polymerases, it 
may prove feasible to inhibit a given polymerase 
activity with the aid of polynucleotide analogues 
which interact with the template, or polymerase, or 
both. One striking feature of RNA tumour viruses is 
the presence in their genomes of poly (A) tracts 25- 
50-fold more extensive than in non-oncogenic viruses 
[ 1121. It had earlier been shown by Tuominen and 
Kenney [ 1131 that single-stranded polyribonucleo- 
tides competitively bind to RLV-DNA polymerase 
and that poly (rU) almost abolished the reverse tran- 
scriptase activity in vitro, independently of the nature 
of the template; under the same conditions DNA 
polymerases from E. coli and mouse embryo cells 
were unaffected. Poly (dU) is also an effective in vitro 
inhibitor of avian myeloblastosis virus reverse transcrip- 
tase [ 1141, suggesting the utility of trials with poly 
(dT), which complexes even more effectively with 
~01~ (A). 
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Can such inhibitors act in vivo, where the situation 
is much more complex? Tennant et al. [ 1151 showed 
that poly (rA) gave 50% inhibition of replication of 
the Mahoney strain of RLV on mouse embryo cells at 
a concentration without effect on the population rate 
growth of the cells. In contrast to the situation in 
vitro, poly (rU) was less effective; while poly (rG) was 
too cytotoxic. It was concluded that poly (rA) sup- 
presses polymerization of virus-specific DNA by inter- 
fering with the function of viral DNA polymerase in 
the cells. Furthermore poly (2’~U-methyl-A) at a 
concentration of lo-50 I.cg/ml inhibited viral replica- 
tion by as much as 90% with no observable toxic 
effects on the cells [ 1161 . The activity in this system 
of poly (2’0methyl-A) excludes possible interferon 
induction, such polymers being inactive. The authors 
do not comment on the lower in vivo activity of poly 
(rU) relative to poly (rA), the reverse of that found in 
vitro; this could be due to susceptibility of poly (rU) 
to intracellular nucleases and suggests trials with poly 
(2’~O-methyl-U) which is completely resistant to 
RNase and highly resistant to other nucleases [ 1171. 
Relatively little has been reported on specific poly- 
nucleotide inhibitors for lytic RNA viruses, such as 
poxvirus, the virions of which contain RNA repli- 
cases. However, by analogy with the situation cited 
above for Q/3 replicase, the development of such inhi- 
bitors’should be feasible (see [ 1181). It may also 
prove advantageous to concentrate on the use of 
deoxypolymers or 2’0-methyl polynucleotides, 
which do not normally exhibit messenger activity 
[ 1191, and are also apparently less toxic to the host 
cells. 
Two additional developments merit comment. 
F’itha et al. [ 1201 have employed vinyl analogues of 
polynucleotides, poly (1 -viriyluracil) and poly 
(I-vinyladenine), with molecular weights in excess of 
10’) as inhibitors of leukemia virus replication. These 
analogues are electrically neutral, resistant to enzymic 
hydrolysis, complex specifically with polynucleotides 
with the expected complementarity, and are appa- 
rently taken up by mammalian cells. Both of these 
significantly inhibited the early stage of acute murine 
leukemia virus infections in mouse embryo cells, but 
did not affect replication of Sindbis and Vesicular 
Stomatitis viruses. Chandra and Bardos [121] and 
Srivasta and Bardos [ 1221 found that synthetic and 
natural polynucleotides, in which some of the uracil 
and/or cytosine residues have been thiolated at the 
5-position, selectively inhibit polymerase activities 
from various sources, including RNA tumour viruses, 
e.g. ‘thiolated’ poly (rC) with 9% of the cytosine 
residues converted to 5-mercaptocytosine equally 
effectively inhibited the DNA-directed DNA poly- 
merases of Friend leukemia virus and murine sarcoma 
virus, but was more effective against the RNA- 
directed DNA polymerase of MSV. Kinetic studies 
indicated that thiolated poly (rC) blocks binding of 
the enzyme to the template. One possible mechanism 
of action is covalent binding of inhibitor to enzyme 
via mixed disulfide linkages [ 1231. While premature 
to predict the possible therapeutic value of such in- 
hibitors, the ability to introduce thiolated residues in 
both model and natural polynucleotides with tailored 
or selected sequences argues in favour of further 
studies in this direction. 
Photodynamic therapy in topical viral infections 
It was shown by Thiele and Wacker [124] that the 
efficacy of IUdR therapy of herpes simplex keratitis 
in man was enhanced by simultaneous exposure to 
light. Although not further explored, this effect is 
readily interpretable if viral DNA incorporation of 
IdUrd occurs, since the incorporated IUdR residues 
absorb at longer wavelengths than thymine residues 
and are susceptible to photochemical reactions involv- 
ing dehalogenation and accompanying strand breaks 
in DNA [ 1251. This is in accord with the known 
increased susceptibility to inactivation of nucleic 
acids, in which thymine residues are replaced by 
5-halogenouracils, by day-light lamps which emit 
traces of radiation down to 300 nm [ 1261. 
A more direct application of light therapy appli- 
cable, as in the foregoing case, to topical viral infec- 
tions, was the use by Moore et al. [ 1271 of profla- 
vine, followed by irradiation with visible light, to 
treat herpes keratitis in the rabbit. An extension of 
this procedure to recurrent herpes simplex infection 
of the skin and mucous membrane in man involved 
the surface application of Neutral Red, followed by 
exposure to visible light. This procedure is based on 
sound theoretical considerations, for the photody- 
namic inactivation of viral infectivity has been known 
for many years and its mechanism reasonably well 
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understood [126,128,129]. The sensitivity of viruses 
to visible light in the presence of a dye is dependent 
on the nature of the dye; with Toluidine Blue, e.g., 
the relative rate constants for inactivation of vaccinia, 
adenoviruses and polioviruses are 1: 0.17 : 0.001, and 
it has been proposed that the relatively high resis- 
tance to photosensitized inactivation of polioviruses 
be profited from to eliminate potentially harmful 
organisms from live polio vaccines [ 1261. 
able being 2,7-bis(2-diethylaminoethoxy)-fluoren-9- 
one dihydrochloride (tilorone hydrochloride), the 
only inducer active orally and, in mice, effective 
against a number of viruses, but least so against the 
influenza group [3,133,134] . Unfortunately this 
inducer has proven less effective in rabbits and had 
little or no measureable ffect in man [6] . 
A more extensive clinical trial of the foregoing 
procedure was conducted by Felber et al. [ 1301 on 
more than 100 patients, with particular emphasis on 
32 with an average of at least four recurrences of 
herpes per year for a minimum of two years. Neutral 
Red was the dye employed, with controls involving 
the use of phenol sulfonphthalein (a red dye with no 
photoreactive or virucidal activity). The results 
reported were impressive, the more so in view of the 
simplicity of the technique. Particularly significant 
was the fact that herpes type 2 virus was even more 
sensitive than type 1, in agreement with the observa- 
tion that both types 1 and 2 were photoinactivated 
equally effectively in tissue culture, this procedure 
being thus effective against type 2 herpes genitalis, 
difficult to treat by other methods. 
It was first shown by Hilleman’s group [ 1351 that 
the most potent synthetic interferon inducers, as 
potent as viruses, are double-stranded polynucleotides 
such as poly (rI)*poly (rC). Since it is technically 
feasible to produce substantial quantities of synthetic 
polynucleotides by polymerization of ribonucleo- 
side-5’-pyrophosphates with polynucleotide phos- 
phorylase or the 5’-triphosphates with polymerases, 
extensive trials have been conducted to examine the 
structural requirements of these polynucleotides for 
inducing activity, as well as increasing activity with 
concomitant decrease in toxicity. Relevant data are 
summarized by DeClercq and Merigan [ 1361, Colby 
[137] and Finter [131]. 
Polynucleotide interferon inducers 
Interferon, produced endogenously by cells during 
virus infections, is a potent antiviral agent with a very 
broad spectrum, relatively stable and generally 
believed to be non-toxic. However, because of its 
species specificity, it was until recently considered 
that only interferon derived from human cells could 
be applied in human diseases, and the prospects, 
based on production from human leucocyte cultures, 
do indeed show promise [6] . More recent data sug- 
gest that certain interferons are active in cells from 
heterologous species [ 13 l] . Nonetheless product@ 
of adequate amounts of interferon for prophylactic 
or therapeutic purposes poses formidable technical 
problems. Hence the widespread interest in interferon 
inducers and attempts to purify and characterize the 
structure and conformation of interferon molecules 
[132]. 
The results of a typical study [ 1381 are shown in 
table 1, from which the following conclusions 
emerge: (a) an increase in stability (or melting tem- 
perature r,) of the double-stranded inducer above a 
given value is of no special significance; (b) blocking 
of the 2’-hydroxyls of the poly (rC) strand dramatic- 
ally decreases or abolishes activity. More recent 
studies with other polynucleotide analogues have 
been reported by Torrence et al. [ 1391 and DeClercq 
and Janik [ 1401. Surprisingly the effects of a 2’-O- 
methyl purine polynucleotide have not yet been 
examined (but see below). It is perhaps not without 
relevance that the 2’-O-methyl polynucleotides are 
also inactive as messengers in in vitro systems [ 1191 
However, W.A. Carter has apparently found that 
replacement of poly (r1) by a copolymer of poly (rI 
and poly (2’QMeI) does not affect activity, while 
simultaneously decreasing toxicity (personal com- 
munication from E. DeClercq). In a paper in press 
[141], it has been shown by means of competition 
experiments that single-stranded polynucleotides do 
not bind to cellular receptor sites for interferon in- 
duction, whereas triple-stranded complexes do bind 
but fail to trigger the necessary message for induc- 
tion. 
Most interferon inducers are polyanions. A few are The structural requirements of poly (rI) * poly (rC) 
low molecular weight substances, the most remark- for interferon induction have been extensively investi- 
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Table 1 
Activity against vesicular stomatitis virus (VSV) in primary rabbit kidney cell cultures of various polynucleotide 1: 1 helical 
complexes, administered as such or by sequential administration of the two components. The Tm values for the helical complexes 
are at pH 7.8 in 0.15 M NaCl 
Polynucleotide Polynucleotide 
no. 1 no. 2 
Minimum inhibitory concentration* (pg/ml) 
Poly no. 1 Poly no. 1, Poly no. 2, 
complexed to then poly then poly 















59 0.04 >lO >lO 
70.5 >lO >lO >lO 
64 0.0004 0.00004 0.0004 
80.5 0.001 0.0004 1 
61.5 4 >lO 4-10 
55 > 10 > 10 >lO 
65 >10 >lO 10 
* Concentration of polymer (either the polynucleotide complex, or polynucleotide no. 2, if polynucleotide no. 2 is added second, 
or polynucleotide no. 1, if polynucleotide no. 1 is added second) required to reduce VSV plaque formation by 50%. 
gated by Carter et al. [ 1421. These authors had pre- 
viously observed that the initial step in induction, 
adsorption of the double-stranded helix, is very rapid 
in human cells in vitro, suggesting that an intact pri- 
mary structure of the inducer complex is required 
only as a triggering event, and that subsequent pre- 
sence of the complex is largely detrimental to the 
cell, including toxicity. They therefore prepared 
double-stranded helices of poly (rI), which has been 
shown to be the component of poly (rI)*poly (rC) 
more effectively adsorbed to the cell receptor site 
[ 1431, with copolymers of C and U, and C and G. 
These exhibited in vitro antiviral activities compar- 
able to poly (rI)*poly (rC), but were hydrolyzed by 
nucleases 5-to Sfold more rapidly. It remains to 
evaluate the efficacy of these new models in vivo, but 
this approach is one of many illustrating the possibili- 
ties of manipulating the polynucleotide inducing 
system. 
The mode of action of interferon, administered as 
such or formed by inducers, is still far from clarified. 
A recent paper [ 1443 , summarizing earlier results, 
reported that vaccinia virion DNA-directed RNA 
polymerase is inhibited after infection if the cells 
were pretreated with interferon or interferon-inducer, 
leading to marked inhibition of vaccinia mRNA for- 
mation. 
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